Kymera Therapeutics (KYMR) shares were up 2.5% in recent Monday trading after Wells Fargo upgraded the stock's rating to overweight.
The firm has a price target of $57 for the company.
Trading volume stood at over 187,000 shares against a daily average of about 418,000 shares.
Price: 48.01, Change: +1.16, Percent Change: +2.47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.